Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Postmarketing Study Oversight To Benefit From Informatics Upgrades

Jul 25 2016

• By Sue Sutter

HHS OIG

Related Content

FDA Should Fine Companies With Late Post-Marketing Studies, HHS OIG Says

Jul 17 2006

Merck’s Postmarketing Study Delays Prompt FDA To Unsheathe New Enforcement Power

Mar 05 2012

Do Drugs Given Expedited Approval Have More Safety Risks? GAO Says FDA Can't Tell

Jan 21 2016

Related Companies

Merck & Co., Inc.

Additional Topics

United States Regulation Drug Safety Post Market Regulation & Studies BioPharmaceutical

More from Drug Safety

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window